A genetic defect in sex cells may predispose to childhood leukemia
Researchers at the Sainte-Justine University Hospital Center and the University of Montreal have found a possible heredity mechanism that predisposes children to acute lymphoblastic leukemia (ALL), the most ...
Genetics
Dec 17, 2012 |
5 / 5 (1) |
0
Iclusig approved for rare leukemias
(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..
Cancer
Dec 16, 2012 |
not rated yet |
0
Vegetable compound could become ingredient to treating leukemia
It looks like your mother was on to something when she said, "Eat your vegetables!" A concentrated form of a compound called sulforaphane found in broccoli and other cruciferous vegetables has been shown to reduce the number o ...
Cancer
Dec 12, 2012 |
5 / 5 (2) |
0
Weekly dose reduces targeted drug's side effects, but not its activity against ALL
A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ...
Cancer
Dec 11, 2012 |
not rated yet |
0
Intensified chemotherapy shows promise for children with very high risk form of leukemia
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical ...
Cancer
Dec 10, 2012 |
not rated yet |
0
Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of ...
Cancer
Dec 10, 2012 |
not rated yet |
0
Leukemia patients remain in remission more than two years after engineered T cell therapy
Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the ...
Cancer
Dec 10, 2012 |
5 / 5 (2) |
0
Reduced intensity regimen prior to marrow transplant better for older leukemia patients
A new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) shows that preparing older acute myeloid ...
Cancer
Dec 10, 2012 |
not rated yet |
0
|
Engineered immune cells produce complete response in child with an aggressive pediatric leukemia
By reprogramming a 7-year-old girl's own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed ...
Cancer
Dec 09, 2012 |
5 / 5 (1) |
0
More than a third of high-risk leukemia patients respond to an experimental new drug
A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial. In more than a third of participants, the leukemia was completely ...
Medications
Dec 09, 2012 |
not rated yet |
0
Pre-clinical data shows Angiocidin effective against leukemia
Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.
Cancer
Dec 09, 2012 |
not rated yet |
0
Genotype predicts treatment related mortality (TRM) in African-American and Asian pediatric AML patients
New research suggests that the presence of a specific genetic marker, known as WT1 SNP rs16754, may be associated with reduced toxicity from chemotherapy in African-American and Asian children with acute myeloid leukemia ...
Cancer
Dec 09, 2012 |
not rated yet |
0
ATRA and arsenic trioxide versus ATRA and idarubicin for newly diagnosed, non high-risk acute promyelocytic
New research demonstrates the efficacy of the first curative treatment for acute promyelocytic leukemia (APL) that does not include chemotherapy, marking an important step toward front-line use of targeted therapies for acute ...
Cancer
Dec 09, 2012 |
not rated yet |
0
Nanotechnology drug delivery shows promise for treatment of pediatric cancer
This month, Molecular Pharmaceutics reported promising findings from the Nemours Center for Childhood Cancer Research and the Materials Science and Engineering Department at the University of Delaware, about the potential for na ...
Cancer
Dec 04, 2012 |
not rated yet |
0
Ponatinib acts against the most resistant types of chronic myeloid leukemia
A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.
Cancer
Nov 28, 2012 |
not rated yet |
0
|
